German biotechnology company MorphoSys AG (MOR, MPSYY.PK) on Wednesday announced that it has entered into a definitive agreement to acquire Constellation Pharmaceuticals, Inc., (CNST) for $34.00 per share in cash, which represents a total equity value of $1.7 billion.
MorphoSys also announced that it has entered into a long-term strategic funding partnership with Royalty Pharma plc (RPRX).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com